Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Some Cancer Patients Found to Continue Shedding the Virus After COVID

Some Cancer Patients Found to Continue Shedding the Virus After COVID

After intensive cancer treatment, people with profound immune suppression and COVID-19 may, for at least 2 months after symptom onset, shed viable SARS-CoV-2 virus and may need prolonged isolation.

Hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy had been received by 18 patients, and lymphoma was present in 2 patients; prolonged viable-virus shedding was detected.

This study was reported on December 1 in the leading medical journal NEJM.

Can the virus continue to be shed after COVID?

We know that people without comorbidities / immunosuppression are no longer infectious after the first week of COVID-19 illness. However, we need awareness of how long immunosuppressed patients can pose an infection risk to others.

The researchers said their previous experience showed that severely immunocompromised patients shed other viruses (such as respiratory syncytial virus, parainfluenza, and influenza) longer than healthy controls.

On the basis of their latest findings, the researchers suggest that current COVID-19 isolation guidelines may need revision for immunosuppressed patients. Even if only a small proportion of cancer patients with COVID-19 remain infectious for a prolonged period, "This is an additional risk we need to address". 

Particularly for hematological cancers, doctors caring for these patients should determine when a transplant recipient can leave isolation by following coronavirus test-based criteria.

Shedding viable virus

For this study, researchers used cell cultures to detect viable virus in serial nasopharyngeal and sputum samples collected from 20 patients with COVID-19 (diagnosed with COVID-19 between March 10 and April 20) and profound immunosuppression (virtually wiped-out immunity).  

Of these 20 patients, 15 were receiving active treatment or chemotherapy; 11 developed severe COVID-19 infection. 

A total of 78 respiratory samples were collected.

Results

  • Viral RNA was detected for up to 78 days after symptom onset, and
  • Viable virus was detected in 10 of the 14 nasopharyngeal samples (71%) available from the first day of laboratory testing.
  • 5 patients were followed, and the team grew virus in culture from these patients for up to 61 days after symptom onset. Of this small group of 5 patients, two had received allogeneic stem cell transplantation, and one patient had received CAR T-cell therapy within the previous 6 months. Interestingly, this patient continued to remain seronegative for antibodies against coronavirus.
  • The team also obtained serial sample genomes for 11 patients and found that patients were not being repeatedly reinfected but continued carrying the same virus. They state that these findings are consistent with persistent infection.

*

RELATED TOPICS

Sources

Teresa Aydillo, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. NEJM, 1 Dec 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Some Cancer Patients Found to Continue Shedding the Virus After COVID

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy